Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.

Oncology (Williston Park, N.Y.) - 11 Feb 2021

Laws Alison, Garrido-Castro Ana, Poorvu Philip, Winer Eric, Mittendorf Elizabeth, King Tari

Abstract excerpt

The 21-gene Recurrence Score (RS) assay has been validated as both a prognostic and predictive tool in node-negative (pN0), estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer. A large body of evidence supports the clinical utility of the RS in the node positive (pN+) population as well. Retrospective analyses of archived tissue from multiple clinical trials have found the RS to be prognostic in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Genetic Predisposition to Disease

Share to Genetic Testing

Share to Lymphatic Metastasis

Share to Predictive Value of Tests

Share to Prognosis

Source

Identifiers

PMID: 33577165
DOI: 10.46883/ONC.2021.3502.0077

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.PMID 33577165Read ↗

Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer PatientsSemantic proximity Read ↗

Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen.Semantic proximity Read ↗

Favorable Locoregional Control in Clinically Node- Negative Hormone-receptor Positive Breast Cancer With Low 21-gene Recurrence Scores: a Single Institutional Study With 10-year Follow-upSemantic proximity Read ↗

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.Semantic proximity Read ↗

Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Semantic proximity Read ↗

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast CancerSemantic proximity Read ↗

The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.Semantic proximity Read ↗

The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer: A National Cancer Database StudySemantic proximity Read ↗

Prospective Validation of a 21-Gene Expression Assay in Breast CancerSemantic proximity Read ↗

21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.Semantic proximity Read ↗

The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in KoreaSemantic proximity Read ↗

The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.